Safety and efficacy of daptomycin in outpatient parenteral antimicrobial therapy: a prospective and multicenter cohort study (DAPTODOM trial)

References

• Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother. 2004;48:63–68.
   PubMed Web of Science ®Google Scholar
• Oleson Jr FB, Berman CL, Kirkpatrick JB, et al. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother. 2000;44:2948–2953.
   PubMed Web of Science ®Google Scholar
• Novartis Europharm, Ltd. Cubicin summary of product characteristics. London: European Medicines Agency; 2016.
   Google Scholar
• Fowler Jr VG, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653–665.
   PubMed Web of Science ®Google Scholar
• Katz DE, Lindfield KC, Steenbergen JN, et al. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. Int J Clin Pract. 2008;62:1455–1464.
   PubMed Web of Science ®Google Scholar
• Martone WJ, Lindfield KC, Katz DE. Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry. Int J Clin Pract. 2008;62:1183–1187.
   PubMed Web of Science ®Google Scholar
• Levine DP, Lamp KC. Daptomycin in the treatment of patients with infective endocarditis: experience from a registry. Am J Med. 2007;120:S28–S33.
   PubMed Web of Science ®Google Scholar
• Gallagher JC, Huntington JA, Culshaw D, et al. Daptomycin therapy for osteomyelitis: a retrospective study. BMC Infect Dis. 2012;12:133.
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Brown J, Lamp KC, et al. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience. Clin Ther. 2009;31:1936–1945.
   PubMed Web of Science ®Google Scholar
• Rehm S, Campion M, Katz DE, et al. Community-based outpatient parenteral antimicrobial therapy (CoPAT) for Staphylococcus aureus bacteraemia with or without infective endocarditis: analysis of the randomized trial comparing daptomycin with standard therapy. J Antimicrob Chemother. 2009;63:1034–1042.
   PubMed Web of Science ®Google Scholar
• Chakraborty A, Roy S, Loeffler J, et al. Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection. J Antimicrob Chemother. 2009;64:151–158.
   PubMed Web of Science ®Google Scholar
• WHO. International monitoring of adverse reactions to drugs: adverse reaction terminology. Uppsala, Sweden: WHO Collaborating Centre for International Drug Monitoring; 1992.
   Google Scholar
• Horcajada JP, Garcia L, Benito N, et al. [Specialized home care for infectious disease. Experience from 1995 to 2002]. Enferm Infecc Microbiol Clin. 2007;25:429–436.
   PubMed Web of Science ®Google Scholar
• Chapman AL, Dixon S, Andrews D, et al. Clinical efficacy and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective. J Antimicrob Chemother. 2009;64:1316–1324.
   PubMed Web of Science ®Google Scholar
• Seaton RA, Sharp E, Bezlyak V, et al. Factors associated with outcome and duration of therapy in outpatient parenteral antibiotic therapy (OPAT) patients with skin and soft-tissue infections. Int J Antimicrob Agents. 2011;38:243–248.
   PubMed Web of Science ®Google Scholar
• Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38:1673–1681.
   PubMed Web of Science ®Google Scholar
• Eleftheriadou I, Tentolouris N, Argiana V, et al. Methicillin-resistant Staphylococcus aureus in diabetic foot infections. Drugs. 2010;70:1785–1797.
   PubMed Web of Science ®Google Scholar
• Arias CA, Panesso D, McGrath DM, et al. Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med. 2011;365:892–900.
   PubMed Web of Science ®Google Scholar
• Cervera C, del Rio A, Garcia L, et al. Efficacy and safety of outpatient parenteral antibiotic therapy for infective endocarditis: a ten-year prospective study. Enferm Infecc Microbiol Clin. 2011;29:587–592.
   PubMed Web of Science ®Google Scholar
• Amodeo MR, Clulow T, Lainchbury J, et al. Outpatient intravenous treatment for infective endocarditis: safety, effectiveness and one-year outcomes. J Infect. 2009;59:387–393.
   PubMed Web of Science ®Google Scholar
• Andrews MM, von Reyn CF. Patient selection criteria and management guidelines for outpatient parenteral antibiotic therapy for native valve infective endocarditis. Clin Infect Dis. 2001;33:203–209.
   PubMed Web of Science ®Google Scholar
• Huminer D, Bishara J, Pitlik S. Home intravenous antibiotic therapy for patients with infective endocarditis. Eur J Clin Microbiol Infect Dis. 1999;18:330–334.
   PubMed Web of Science ®Google Scholar
• Larioza J, Heung L, Girard A, et al. Management of infective endocarditis in outpatients: clinical experience with outpatient parenteral antibiotic therapy. South Med J. 2009;102:575–579.
   PubMed Web of Science ®Google Scholar
• Monteiro CA, Cobbs CG. Outpatient management of infective endocarditis. Curr Infect Dis Rep. 2001;3:319–327.
   PubMedGoogle Scholar
• Cervera C, Castaneda X, Pericas JM, et al. Clinical utility of daptomycin in infective endocarditis caused by Gram-positive cocci. Int J Antimicrob Agents. 2011;38:365–370.
   PubMed Web of Science ®Google Scholar
• Garcia-de-la-Maria C, Marco F, Armero Y, et al. Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis. Antimicrob Agents Chemother. 2010;54:2781–2786.
   PubMed Web of Science ®Google Scholar
• Corey GR, Kabler H, Mehra P; SOLO I Investigators, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med. 2014;370:2180–2190.
   PubMed Web of Science ®Google Scholar
• Boucher HW, Wilcox M, Talbot GH, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370:2169–2179.
   PubMed Web of Science ®Google Scholar